Skip to main content

Advertisement

Springer Nature Link
Log in

Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine

  • Review
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

Abstract

Frontotemporal lobar degeneration (FTLD) comprises two main classes of neurodegenerative diseases characterized by neuronal/glial proteinaceous inclusions (i.e., proteinopathies) including tauopathies (i.e., FTLD-Tau) and TDP-43 proteinopathies (i.e., FTLD-TDP) while other very rare forms of FTLD are known such as FTLD with FUS pathology (FTLD-FUS). This review focuses mainly on FTLD-Tau and FLTD-TDP, which may present as several clinical syndromes: a behavioral/dysexecutive syndrome (behavioral variant frontotemporal dementia); language disorders (primary progressive aphasia variants); and motor disorders (amyotrophic lateral sclerosis, corticobasal syndrome, progressive supranuclear palsy syndrome). There is considerable heterogeneity in clinical presentations of underlying neuropathology and current clinical criteria do not reliably predict underlying proteinopathies ante-mortem. In contrast, molecular etiologies of hereditary FTLD are consistently associated with specific proteinopathies. These include MAPT mutations with FTLD-Tau and GRN, C9orf72, VCP and TARDBP with FTLD-TDP. The last decade has seen a rapid expansion in our knowledge of the molecular pathologies associated with this clinically and neuropathologically heterogeneous group of FTLD diseases. Moreover, in view of current limitations to reliably diagnose specific FTLD neuropathologies prior to autopsy, we summarize the current state of the science in FTLD biomarker research including neuroimaging, biofluid and genetic analyses. We propose that combining several of these biomarker modalities will improve diagnostic specificity in FTLD through a personalized medicine approach. The goals of these efforts are to enhance power for clinical trials focused on slowing or preventing progression of spread of tau, TDP-43 and other FTLD-associated pathologies and work toward the goal of defining clinical endophenotypes of FTD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ahmed Z, Bigio EH, Budka H, Dickson DW, Ferrer I, Ghetti B, Giaccone G, Hatanpaa KJ, Holton JL, Josephs KA et al (2013) Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol 126:537–544. doi:10.1007/s00401-013-1171-0

    PubMed Central  PubMed  Google Scholar 

  2. Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, Rogelj B, Al-Chalabi A, Hortobagyi T, Shaw CE (2011) p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol 122:691–702. doi:10.1007/s00401-011-0911-2

    CAS  PubMed  Google Scholar 

  3. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR (2007) Focal cortical presentations of Alzheimer’s disease. Brain 130:2636–2645. doi:10.1093/brain/awm213

    CAS  PubMed  Google Scholar 

  4. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445. doi:10.1002/ana.21154

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611. doi:10.1016/j.bbrc.2006.10.093

    CAS  PubMed  Google Scholar 

  6. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496–503. doi:10.1212/WNL.0b013e31827f0fd1

    PubMed Central  PubMed  Google Scholar 

  7. Armstrong R, Cairns N, Lantos P (1999) The spatial patterns of Pick bodies, Pick cells and Alzheimer’s disease pathology in Pick’s disease. Neuropathology 19:64–70. doi:10.1046/j.1440-1789.1999.00219.x

    CAS  PubMed  Google Scholar 

  8. Armstrong RA, Cairns NJ (2012) Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders. J Neural Transm 119:1551–1560. doi:10.1007/s00702-012-0838-3

    CAS  PubMed  Google Scholar 

  9. Armstrong RA, Cairns NJ, Lantos PL (1999) Laminar distribution of pick bodies, pick cells and Alzheimer disease pathology in the frontal and temporal cortex in Pick’s disease. Neuropathol Appl Neurobiol 25:266–271

    CAS  PubMed  Google Scholar 

  10. Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW 3rd, Rademakers R et al (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77:639–646. doi:10.1016/j.neuron.2013.02.004

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Baborie A, Griffiths TD, Jaros E, Perry R, McKeith IG, Burn DJ, Masuda-Suzukake M, Hasegawa M, Rollinson S, Pickering-Brown Set al (2014) Accumulation of dipeptide repeat proteins predates that of TDP-43 in Frontotemporal Lobar Degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene. Neuropathol Appl Neurobiol. doi:10.1111/nan.12178

  12. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8:711–715

    CAS  PubMed  Google Scholar 

  13. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919. doi:10.1038/nature05016

    CAS  PubMed  Google Scholar 

  14. Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J, Borg A, Fratta P et al (2013) Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet 92:345–353. doi:10.1016/j.ajhg.2013.01.011

    PubMed Central  CAS  PubMed  Google Scholar 

  15. Behrens MI, Mukherjee O, Tu PH, Liscic RM, Grinberg LT, Carter D, Paulsmeyer K, Taylor-Reinwald L, Gitcho M, Norton JB et al (2007) Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. Alzheimer Dis Assoc Disord 21:1–7. doi:10.1097/WAD.0b013e31803083f2

    PubMed  Google Scholar 

  16. Bell K, Cairns NJ, Lantos PL, Rossor MN (2000) Immunohistochemistry distinguishes: between Pick’s disease and corticobasal degeneration. J Neurol Neurosurg Psychiatry 69:835–836

    PubMed Central  CAS  PubMed  Google Scholar 

  17. Berry RW, Sweet AP, Clark FA, Lagalwar S, Lapin BR, Wang T, Topgi S, Guillozet-Bongaarts AL, Cochran EJ, Bigio EH et al (2004) Tau epitope display in progressive supranuclear palsy and corticobasal degeneration. J Neurocytol 33:287–295. doi:10.1023/B:NEUR.0000044190.96426.b9

    CAS  PubMed  Google Scholar 

  18. Bhardwaj A, Myers MP, Buratti E, Baralle FE (2013) Characterizing TDP-43 interaction with its RNA targets. Nucleic Acids Res 41:5062–5074. doi:10.1093/nar/gkt189

    PubMed Central  CAS  PubMed  Google Scholar 

  19. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S et al (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70:1827–1835. doi:10.1212/01.wnl.0000311445.21321.fc

    PubMed Central  CAS  PubMed  Google Scholar 

  20. Bieniek KF, van Blitterswijk M, Baker MC, Petrucelli L, Rademakers R, Dickson DW (2014) Expanded C9ORF72 hexanucleotide repeat in depressive pseudodementia. JAMA Neurol 71:775–781. doi:10.1001/jamaneurol.2013.6368

    PubMed Central  PubMed  Google Scholar 

  21. Bigio EH, Wu JY, Deng HX, Bit-Ivan EN, Mao Q, Ganti R, Peterson M, Siddique N, Geula C, Siddique T et al (2013) Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol 125:463–465. doi:10.1007/s00401-013-1089-6

    PubMed Central  PubMed  Google Scholar 

  22. Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-Hernandez M, Knopman DS, Pedraza O, Vemuri P, Jones D, Lowe V, Murray ME et al (2012) Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135:765–783. doi:10.1093/brain/aws004

    PubMed Central  PubMed  Google Scholar 

  23. Borroni B, Gardoni F, Parnetti L, Magno L, Malinverno M, Saggese E, Calabresi P, Spillantini MG, Padovani A, Di Luca M (2009) Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 30:34–40. doi:10.1016/j.neurobiolaging.2007.05.009

    CAS  PubMed  Google Scholar 

  24. Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, Premi E, Bonuccelli U, Grassi M, Perani D, Calabresi P et al (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71:1796–1803. doi:10.1212/01.wnl.0000335941.68602.39

    CAS  PubMed  Google Scholar 

  25. Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M et al (2012) Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimer’s Dement J Alzheimer’s Assoc. doi:10.1016/j.jalz.2012.03.002

    Google Scholar 

  26. Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A et al (2012) The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimer’s Dement J Alzheimer’s Assoc. doi:10.1016/j.jalz.2012.03.003

    Google Scholar 

  27. Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK et al (2013) Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 12:149–156. doi:10.1016/S1474-4422(12)70320-4

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR et al (2014) Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 13:676–685. doi:10.1016/S1474-4422(14)70088-2

    CAS  PubMed  Google Scholar 

  29. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259

    CAS  PubMed  Google Scholar 

  30. Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K (2013) Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. Nat Rev Neurol 9:708–714. doi:10.1038/nrneurol.2013.221

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Braak H, Del Tredici K (2014) Are cases with tau pathology occurring in the absence of Abeta deposits part of the AD-related pathological process? Acta Neuropathol. doi:10.1007/s00401-014-1356-1

  32. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 10:1089–1099

    CAS  PubMed  Google Scholar 

  33. Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, Fang L, Van Deerlin VM, Ludolph AC, Lee VM et al (2014) Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 127:423–439. doi:10.1007/s00401-013-1238-y

    PubMed Central  CAS  PubMed  Google Scholar 

  34. Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM, Wood EM, Baek Yet al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. doi:10.1002/ana.23937

  35. Brettschneider J, Tredici KD, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM, Wood EM, Baek Yet al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. doi:10.1002/ana.23937

  36. Brettschneider J, Van Deerlin VM, Robinson JL, Kwong L, Lee EB, Ali YO, Safren N, Monteiro MJ, Toledo JB, Elman L et al (2012) Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol 123:825–839. doi:10.1007/s00401-012-0970-z

    PubMed Central  PubMed  Google Scholar 

  37. Brunden KR, Trojanowski JQ, Smith AB 3rd, Lee VM, Ballatore C (2014) Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. Bioorg Med Chem 22:5040–5049. doi:10.1016/j.bmc.2013.12.046

    CAS  PubMed  Google Scholar 

  38. Buratti E, Baralle FE (2001) Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 276:36337–36343. doi:10.1074/jbc.M104236200

    CAS  PubMed  Google Scholar 

  39. Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C et al (2012) Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 11:232–240. doi:10.1016/S1474-4422(12)70014-5

    PubMed Central  CAS  PubMed  Google Scholar 

  40. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL 3rd, Schneider JA, Grinberg LT, Halliday G et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114:5–22. doi:10.1007/s00401-007-0237-2

    PubMed Central  PubMed  Google Scholar 

  41. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, Foong C, White CL 3rd, Schneider JA, Kretzschmar HA et al (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:227–240. doi:10.2353/ajpath.2007.070182

    PubMed Central  CAS  PubMed  Google Scholar 

  42. Cairns NJ, Perrin RJ, Schmidt RE, Gru A, Green KG, Carter D, Taylor-Reinwald L, Morris JC, Gitcho MA, Baloh RH (2010) TDP-43 proteinopathy in familial motor neurone disease with TARDBP A315T mutation: a case report. Neuropathol Appl Neurobiol 36:673–679. doi:10.1111/j.1365-2990.2010.01121.x

    PubMed Central  CAS  PubMed  Google Scholar 

  43. Chen-Plotkin AS, Martinez-Lage M, Sleiman PM, Hu W, Greene R, Wood EM, Bing S, Grossman M, Schellenberg GD, Hatanpaa KJ et al (2011) Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol 68:488–497. doi:10.1001/archneurol.2011.53

    PubMed Central  PubMed  Google Scholar 

  44. Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L, Busch JI, Akle S, Grossman M, Van Deerlin V et al (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 32:11213–11227. doi:10.1523/JNEUROSCI.0521-12.2012

    PubMed Central  CAS  PubMed  Google Scholar 

  45. Chen-Plotkin AS, Xiao J, Geser F, Martinez-Lage M, Grossman M, Unger T, Wood EM, Van Deerlin VM, Trojanowski JQ, Lee VM (2010) Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. Acta Neuropathol 119:111–122. doi:10.1007/s00401-009-0576-2

    PubMed Central  CAS  PubMed  Google Scholar 

  46. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A et al (2014) Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimer’s Dis 38:171–184. doi:10.3233/JAD-130098

    Google Scholar 

  47. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 11:669–678. doi:10.1016/S1474-4422(12)70142-4

    CAS  PubMed  Google Scholar 

  48. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M et al (2013) Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA 110:9535–9540. doi:10.1073/pnas.1301175110

    PubMed Central  CAS  PubMed  Google Scholar 

  49. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, Lee VM (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252. doi:10.1038/ncomms1255

    PubMed Central  PubMed  Google Scholar 

  50. Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, Davis M, Dickson D, Jarpe M, DeTure M et al (2014) Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 23:104–116. doi:10.1093/hmg/ddt402

    PubMed Central  CAS  PubMed  Google Scholar 

  51. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EHet al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. doi:10.1007/s00401-014-1349-0

  52. Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N, Bertelsen S, Mayo K, Norton JB, Morris JC et al (2011) Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 68:581–586. doi:10.1001/archneurol.2010.350

    PubMed Central  PubMed  Google Scholar 

  53. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924. doi:10.1038/nature05017

    CAS  PubMed  Google Scholar 

  54. Dai RM, Li CC (2001) Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin–proteasome degradation. Nat Cell Biol 3:740–744. doi:10.1038/35087056

    CAS  PubMed  Google Scholar 

  55. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256. doi:10.1016/j.neuron.2011.09.011

    PubMed Central  CAS  PubMed  Google Scholar 

  56. Delacourte A, Robitaille Y, Sergeant N, Buee L, Hof PR, Wattez A, Laroche-Cholette A, Mathieu J, Chagnon P, Gauvreau D (1996) Specific pathological Tau protein variants characterize Pick’s disease. J Neuropathol Exp Neurol 55:159–168

    CAS  PubMed  Google Scholar 

  57. Dickson DW, Kouri N, Murray ME, Josephs KA (2011) Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 45:384–389. doi:10.1007/s12031-011-9589-0

    PubMed Central  CAS  PubMed  Google Scholar 

  58. Dopper EG, Rombouts SA, Jiskoot LC, den Heijer T, de Graaf JR, de Koning I, Hammerschlag AR, Seelaar H, Seeley WW, Veer IM et al (2014) Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology 83:e19–e26. doi:10.1212/WNL.0000000000000583

    PubMed  Google Scholar 

  59. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM et al (2014) Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 13:686–699. doi:10.1016/S1474-4422(14)70065-1

    PubMed  Google Scholar 

  60. Ferrer I, Santpere G, van Leeuwen FW (2008) Argyrophilic grain disease. Brain 131:1416–1432. doi:10.1093/brain/awm305

    PubMed  Google Scholar 

  61. Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC et al (2009) Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132:583–591. doi:10.1093/brain/awn352

    PubMed Central  PubMed  Google Scholar 

  62. Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus-Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L et al (2011) TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76:467–474. doi:10.1212/WNL.0b013e31820a0e3b

    PubMed Central  CAS  PubMed  Google Scholar 

  63. Forman M, Trojanoswki JQ, Lee VM-Y (2004) Hereditary tauopathies and idiopathic frontotemporal dementias. Cambridge University Press, London

  64. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, Chatterjee A, Hurtig HI, Karlawish JH, Rosen HJ et al (2006) Frontotemporal dementia: clinicopathological correlations. Ann Neurol 59:952–962. doi:10.1002/ana.20873

    PubMed Central  PubMed  Google Scholar 

  65. Forman MS, Zhukareva V, Bergeron C, Chin SS, Grossman M, Clark C, Lee VM, Trojanowski JQ (2002) Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol 160:2045–2053. doi:10.1016/S0002-9440(10)61154-6

    PubMed Central  CAS  PubMed  Google Scholar 

  66. Foulds P, McAuley E, Gibbons L, Davidson Y, Pickering-Brown SM, Neary D, Snowden JS, Allsop D, Mann DM (2008) TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer’s disease and frontotemporal lobar degeneration. Acta Neuropathol 116:141–146. doi:10.1007/s00401-008-0389-8

    PubMed Central  CAS  PubMed  Google Scholar 

  67. Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, Frosch MP (2008) TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol 67:62–67. doi:10.1097/nen.0b013e3181609361

    CAS  PubMed  Google Scholar 

  68. Fujishiro H, Uchikado H, Arai T, Hasegawa M, Akiyama H, Yokota O, Tsuchiya K, Togo T, Iseki E, Hirayasu Y (2009) Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol 117:151–158. doi:10.1007/s00401-008-0463-2

    CAS  PubMed  Google Scholar 

  69. Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-Sarraj S, Neumann M, Gelpi E, Ghetti B et al (2014) TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol 127:407–418. doi:10.1007/s00401-013-1239-x

    PubMed Central  CAS  PubMed  Google Scholar 

  70. Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes-Casey M, Chew J et al (2013) Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 126:829–844. doi:10.1007/s00401-013-1192-8

    PubMed Central  CAS  PubMed  Google Scholar 

  71. Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, Xie SX, Kwong LK, Elman L, McCluskey L et al (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66:180–189. doi:10.1001/archneurol.2008.558

    PubMed Central  PubMed  Google Scholar 

  72. Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM, Garruto RM, Perl DP, Galasko D, Lee VM et al (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115:133–145. doi:10.1007/s00401-007-0257-y

    CAS  PubMed  Google Scholar 

  73. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, Hatanpaa KJ, White CL 3rd, Bigio EH, Caselli R et al (2008) TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 63:535–538. doi:10.1002/ana.21344

    PubMed Central  CAS  PubMed  Google Scholar 

  74. Goldman JS, Quinzii C, Dunning-Broadbent J, Waters C, Mitsumoto H, Brannagan TH 3rd, Cosentino S, Huey ED, Nagy P, Kuo SH (2014) Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol 71:771–774. doi:10.1001/jamaneurol.2013.5762

    PubMed Central  PubMed  Google Scholar 

  75. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014. doi:10.1212/WNL.0b013e31821103e6

    PubMed Central  PubMed  Google Scholar 

  76. Grinberg LT, Wang X, Wang C, Sohn PD, Theofilas P, Sidhu M, Arevalo JB, Heinsen H, Huang EJ, Rosen H et al (2013) Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol 125:581–593. doi:10.1007/s00401-013-1080-2

    PubMed Central  CAS  PubMed  Google Scholar 

  77. Grossman M (2011) Biomarkers to identify the pathological basis for frontotemporal lobar degeneration. J Mol Neurosci 45:366–371. doi:10.1007/s12031-011-9597-0

    PubMed Central  CAS  PubMed  Google Scholar 

  78. Grossman M (2010) Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol 6:88–97. doi:10.1038/nrneurol.2009.216

    PubMed Central  PubMed  Google Scholar 

  79. Grossman M, Elman L, McCluskey L, McMillan CT, Boller A, Powers J, Rascovsky K, Hu W, Shaw L, Irwin DJ et al (2014) Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol 71:442–448. doi:10.1001/jamaneurol.2013.6064

    PubMed Central  PubMed  Google Scholar 

  80. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Coslett HB, Chatterjee A et al (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol 57:721–729. doi:10.1002/ana.20477

    PubMed  Google Scholar 

  81. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, Cahill ME, Bigio EH, Berry RW, Binder LI (2005) Tau truncation during neurofibrillary tangle evolution in Alzheimer’s disease. Neurobiol Aging 26:1015–1022. doi:10.1016/j.neurobiolaging.2004.09.019

    CAS  PubMed  Google Scholar 

  82. Guillozet-Bongaarts AL, Glajch KE, Libson EG, Cahill ME, Bigio E, Berry RW, Binder LI (2007) Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathol 113:513–520. doi:10.1007/s00401-007-0209-6

    CAS  PubMed  Google Scholar 

  83. Guo JL, Lee VM (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20:130–138. doi:10.1038/nm.3457

    PubMed Central  CAS  PubMed  Google Scholar 

  84. Guo JL, Lee VM (2013) Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett 587:717–723. doi:10.1016/j.febslet.2013.01.051

    PubMed Central  CAS  PubMed  Google Scholar 

  85. Harms M, Benitez BA, Cairns N, Cooper B, Cooper P, Mayo K, Carrell D, Faber K, Williamson J, Bird T et al (2013) C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol 70:736–741. doi:10.1001/2013.jamaneurol.537

    PubMed Central  PubMed  Google Scholar 

  86. Hart MP, Brettschneider J, Lee VM, Trojanowski JQ, Gitler AD (2012) Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. Acta Neuropathol 124:221–230. doi:10.1007/s00401-012-0985-5

    PubMed Central  CAS  PubMed  Google Scholar 

  87. Hensman Moss DJ, Poulter M, Beck J, Hehir J, Polke JM, Campbell T, Adamson G, Mudanohwo E, McColgan P, Haworth A et al (2014) C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 82:292–299. doi:10.1212/WNL.0000000000000061

    PubMed Central  CAS  PubMed  Google Scholar 

  88. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, Kril JJ, Halliday GM (2004) Clinicopathological correlates in frontotemporal dementia. Ann Neurol 56:399–406. doi:10.1002/ana.20203

    PubMed  Google Scholar 

  89. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE et al (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43:699–705. doi:10.1038/ng.859

    PubMed Central  PubMed  Google Scholar 

  90. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A et al (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914–1917

    CAS  PubMed  Google Scholar 

  91. Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, LightFoot R, Bellmann C, Richter-Landsberg C, Lee VM, Trojanowski JQ (2003) Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 163:1021–1031. doi:10.1016/S0002-9440(10)63462-1

    PubMed Central  CAS  PubMed  Google Scholar 

  92. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A et al (2001) Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56:1702–1706

    CAS  PubMed  Google Scholar 

  93. Hsiung GY, DeJesus-Hernandez M, Feldman HH, Sengdy P, Bouchard-Kerr P, Dwosh E, Butler R, Leung B, Fok A, Rutherford NJ et al (2012) Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain 135:709–722. doi:10.1093/brain/awr354

    PubMed Central  PubMed  Google Scholar 

  94. Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM, McCluskey L, Elman L, Hurtig HI, Siderowf A et al (2010) Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 75:2079–2086. doi:10.1212/WNL.0b013e318200d78d

    PubMed Central  CAS  PubMed  Google Scholar 

  95. Hu WT, McMillan C, Libon D, Leight S, Forman M, Lee VM, Trojanowski JQ, Grossman M (2010) Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology 75:595–602. doi:10.1212/WNL.0b013e3181ed9c52

    PubMed Central  CAS  PubMed  Google Scholar 

  96. Hu WT, Seelaar H, Josephs KA, Knopman DS, Boeve BF, Sorenson EJ, McCluskey L, Elman L, Schelhaas HJ, Parisi JE et al (2009) Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol 66:1359–1364. doi:10.1001/archneurol.2009.253

    PubMed Central  PubMed  Google Scholar 

  97. Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, Shelnutt M, Van Deerlin V, Trojanoswki JQ, Levey AI (2013) Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology (in press)

  98. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci 33:1024–1037. doi:10.1523/JNEUROSCI.2642-12.2013

    PubMed Central  CAS  PubMed  Google Scholar 

  99. Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, Clark CM, Elman LB, Miller BL, Grossman M et al (2008) Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol 173:182–194. doi:10.2353/ajpath.2008.080003

    PubMed Central  CAS  PubMed  Google Scholar 

  100. Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, Lee VM, Trojanowski JQ (2013) Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 70:462–468. doi:10.1001/jamaneurol.2013.1933

    PubMed Central  PubMed  Google Scholar 

  101. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, McCarty-Wood E, Van Deerlin VM, Lee VM, Trojanowski JQ (2013) Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am J Pathol 183:344–351. doi:10.1016/j.ajpath.2013.04.025

    PubMed Central  CAS  PubMed  Google Scholar 

  102. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, Trojanowski JQ (2012) Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain 135:807–818. doi:10.1093/brain/aws013

    PubMed Central  PubMed  Google Scholar 

  103. Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toledo JB, Boller A, Bekisz J, Chandrasekaran K et al (2013) Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 84:163–169. doi:10.1136/jnnp-2012-303507

    PubMed Central  PubMed  Google Scholar 

  104. Irwin DJ, McMillan CT, Suh E, Powers J, Rascovsky K, Wood EM, Toledo JB, Arnold SE, Lee VM, Van Deerlin VM et al (2014) Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. Neurology 83:502–509. doi:10.1212/WNL.0000000000000668

    CAS  PubMed  Google Scholar 

  105. Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, Van Deerlin V, Lee VM, Trojanowski JQ, Grossman M (2012) Comparison of cerebrospinal fluid levels of tau and Abeta 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol 69:1018–1025. doi:10.1001/archneurol.2012.26

    PubMed Central  PubMed  Google Scholar 

  106. Irwin DJ, Trojanowski JQ, Grossman M (2013) Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer’s disease. Front Aging Neurosci 5:6. doi:10.3389/fnagi.2013.00006

    PubMed Central  CAS  PubMed  Google Scholar 

  107. Jellinger KA, Attems J (2007) Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol 113:107–117. doi:10.1007/s00401-006-0156-7

    CAS  PubMed  Google Scholar 

  108. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J et al (2010) Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68:857–864. doi:10.1016/j.neuron.2010.11.036

    PubMed Central  CAS  PubMed  Google Scholar 

  109. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, Hauser MF, Witte RJ, Boeve BF, Knopman DS et al (2006) Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 129:1385–1398. doi:10.1093/brain/awl078

    PubMed Central  PubMed  Google Scholar 

  110. Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, Petersen RC, Dickson DW (2014) Staging TDP-43 pathology in Alzheimer’s disease. Acta Neuropathol 127:441–450. doi:10.1007/s00401-013-1211-9

    PubMed Central  CAS  PubMed  Google Scholar 

  111. Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF et al (2014) TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol 127:811–824. doi:10.1007/s00401-014-1269-z

    CAS  PubMed  Google Scholar 

  112. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45–51. doi:10.1038/nature12481

    PubMed Central  CAS  PubMed  Google Scholar 

  113. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F et al (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40:572–574. doi:10.1038/ng.132

    CAS  PubMed  Google Scholar 

  114. Kalkonde YV, Jawaid A, Qureshi SU, Shirani P, Wheaton M, Pinto-Patarroyo GP, Schulz PE (2012) Medical and environmental risk factors associated with frontotemporal dementia: a case–control study in a veteran population. Alzheimer’s Dement J Alzheimer’s Assoc 8:204–210. doi:10.1016/j.jalz.2011.03.011

    Google Scholar 

  115. Kamada M, Izumi Y, Ayaki T, Nakamura M, Kagawa S, Kudo E, Sako W, Maruyama H, Nishida Y, Kawakami H et al (2014) Clinicopathologic features of autosomal recessive amyotrophic lateral sclerosis associated with optineurin mutation. Neuropathology 34:64–70. doi:10.1111/neup.12051

    CAS  PubMed  Google Scholar 

  116. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM (2013) Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1–42) and tau proteins as Alzheimer disease biomarkers. Clin Chem 59:903–916. doi:10.1373/clinchem.2013.202937

    PubMed Central  CAS  PubMed  Google Scholar 

  117. Khan BK, Yokoyama JS, Takada LT, Sha SJ, Rutherford NJ, Fong JC, Karydas AM, Wu T, Ketelle RS, Baker MC et al (2012) Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry 83:358–364. doi:10.1136/jnnp-2011-301883

    PubMed Central  PubMed  Google Scholar 

  118. Kipps CM, Hodges JR, Hornberger M (2010) Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the ‘bvFTD phenocopy syndrome’. Curr Opin Neurol 23:628–632. doi:10.1097/WCO.0b013e3283404309

    PubMed  Google Scholar 

  119. Kirby J, Highley JR, Cox L, Goodall EF, Hewitt C, Hartley JA, Hollinger HC, Fox M, Ince PG, McDermott CJ et al (2013) Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation. Neuropathol Appl Neurobiol 39:562–571. doi:10.1111/nan.12007

    PubMed Central  CAS  PubMed  Google Scholar 

  120. Knibb JA, Xuereb JH, Patterson K, Hodges JR (2006) Clinical and pathological characterization of progressive aphasia. Ann Neurol 59:156–165. doi:10.1002/ana.20700

    PubMed  Google Scholar 

  121. Knopman DS (1993) Overview of dementia lacking distinctive histology: pathological designation of a progressive dementia. Dementia 4:132–136

    CAS  PubMed  Google Scholar 

  122. Knopman DS, Roberts RO (2011) Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci 45:330–335. doi:10.1007/s12031-011-9538-y

    PubMed Central  CAS  PubMed  Google Scholar 

  123. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T et al (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205–1208. doi:10.1126/science.1166066

    CAS  PubMed  Google Scholar 

  124. Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL (2014) Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345:1139–1145. doi:10.1126/science.1254917

    CAS  PubMed  Google Scholar 

  125. Kwong LK, Irwin DJ, Walker AK, Xu Y, Riddle DM, Trojanowski JQ, Lee VM (2014) Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. Acta Neuropathol Commun 2:33. doi:10.1186/2051-5960-2-33

    PubMed Central  PubMed  Google Scholar 

  126. Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C et al (2011) A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 134:2548–2564. doi:10.1093/brain/awr160

    PubMed Central  PubMed  Google Scholar 

  127. Le Ber I, Camuzat A, Guillot-Noel L, Hannequin D, Lacomblez L, Golfier V, Puel M, Martinaud O, Deramecourt V, Rivaud-Pechoux S et al (2013) C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimer’s Dis 34:485–499. doi:10.3233/JAD-121456

    Google Scholar 

  128. Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, Hahn-Barma V, van der Zee J, Clot F, Bakchine S et al (2008) Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 131:732–746. doi:10.1093/brain/awn012

    PubMed  Google Scholar 

  129. Ledesma MD, Perez M, Colaco C, Avila J (1998) Tau glycation is involved in aggregation of the protein but not in the formation of filaments. Cell Mol Biol 44:1111–1116

    CAS  PubMed  Google Scholar 

  130. Lee EB, Lee VM, Trojanowski JQ (2012) Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 13:38–50. doi:10.1038/nrn3121

    CAS  Google Scholar 

  131. Lee EB, Russ J, Jung H, Elman LB, Chahine LM, Kremens D, Miller BL, Branch Coslett H, Trojanowski JQ, Van Deerlin VM et al (2013) Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U. Acta Neuropathol Commun 1:1–11. doi:10.1186/2051-5960-1-9

    PubMed  Google Scholar 

  132. Lee SE, Khazenzon AM, Trujillo AJ, Guo CC, Yokoyama JS, Sha SJ, Takada LT, Karydas AM, Block NR, Coppola G et al (2014) Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain 137:3047–3060. doi:10.1093/brain/awu248

    PubMed  Google Scholar 

  133. Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, Huang EJ, Trojanowski JQ, Growdon ME, Jang JY et al (2011) Clinicopathological correlations in corticobasal degeneration. Ann Neurol 70:327–340. doi:10.1002/ana.22424

    PubMed Central  PubMed  Google Scholar 

  134. Lee V, Brunden K, Hutton M, Trojanoswki JQ (2012) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. In: Selkoe D, Holtzman DM, Mandelkow E (eds) The biology of Alzheimer disease, 1st edn. Cold Spring Harbor Laboratory Press, New York, pp 416–438

  135. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1–9

    CAS  PubMed  Google Scholar 

  136. Liu EY, Russ J, Wu K, Neal D, Suh E, McNally AG, Irwin DJ, Van Deerlin VM, Lee EB (2014) C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol 128:525–541. doi:10.1007/s00401-014-1286-y

    CAS  PubMed  Google Scholar 

  137. Luk C, Compta Y, Magdalinou N, Marti MJ, Hondhamuni G, Zetterberg H, Blennow K, Constantinescu R, Pijnenburg Y, Mollenhauer B et al (2012) Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 123:396–405. doi:10.1111/j.1471-4159.2012.07911.x

    CAS  PubMed  Google Scholar 

  138. Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, Weng SM, Haass C, Kretzschmar HA, Edbauer D et al (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol 126:859–879. doi:10.1007/s00401-013-1181-y

    CAS  PubMed  Google Scholar 

  139. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113. doi:10.1007/s00401-011-0845-8

    PubMed Central  PubMed  Google Scholar 

  140. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4. doi:10.1007/s00401-009-0612-2

    PubMed Central  PubMed  Google Scholar 

  141. Mahoney CJ, Beck J, Rohrer JD, Lashley T, Mok K, Shakespeare T, Yeatman T, Warrington EK, Schott JM, Fox NC et al (2012) Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 135:736–750. doi:10.1093/brain/awr361

    PubMed Central  PubMed  Google Scholar 

  142. Majounie E, Abramzon Y, Renton AE, Perry R, Bassett SS, Pletnikova O, Troncoso JC, Hardy J, Singleton AB, Traynor BJ (2012) Repeat expansion in C9ORF72 in Alzheimer’s disease. N Engl J Med 366:283–284. doi:10.1056/NEJMc1113592

    PubMed Central  CAS  PubMed  Google Scholar 

  143. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A, Restagno G, Nicolaou N, Simon-Sanchez J et al (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 11:323–330. doi:10.1016/S1474-4422(12)70043-1

    PubMed Central  CAS  PubMed  Google Scholar 

  144. Mann DM, Rollinson S, Robinson A, Bennion Callister J, Thompson JC, Snowden JS, Gendron T, Petrucelli L, Masuda-Suzukake M, Hasegawa M et al (2013) Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun 1:68. doi:10.1186/2051-5960-1-68

    PubMed Central  PubMed  Google Scholar 

  145. Martinez-Lage M, Molina-Porcel L, Falcone D, McCluskey L, Lee VM, Van Deerlin VM, Trojanowski JQ (2012) TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation. Acta Neuropathol 124:285–291. doi:10.1007/s00401-012-0947-y

    PubMed Central  CAS  PubMed  Google Scholar 

  146. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108. doi:10.1016/j.neuron.2013.07.037

    CAS  PubMed  Google Scholar 

  147. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S et al (2011) The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer’s Dement J Alzheimer’s Assoc 7(386–395):e386. doi:10.1016/j.jalz.2011.05.2243

    Google Scholar 

  148. McCluskey L, Vandriel S, Elman L, Van Deerlin VM, Powers J, Boller A, Wood EM, Woo J, McMillan CT, Rascovsky K et al (2014) ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. J Neurol Sci 345:118–124. doi:10.1016/j.jns.2014.07.022

    PubMed  Google Scholar 

  149. McMillan C, Irwin D, Avants B, Powers J, Cook PA, McCarty Wood E, Van Deerlin V, Lee V, Trojanoswki JQ, Grossman M (2013) White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry (under review)

  150. McMillan CT, Avants B, Irwin DJ, Toledo JB, Wolk DA, Van Deerlin VM, Shaw LM, Trojanoswki JQ, Grossman M (2012) Can MRI screen for CSF biomarkers in neurodegenerative disease? Neurology. doi:10.1212/WNL.0b013e31827b9147

  151. McMillan CT, Avants BB, Cook P, Ungar L, Trojanowski JQ, Grossman M (2014) The power of neuroimaging biomarkers for screening frontotemporal dementia. Hum Brain Mapp 35:4827–4840. doi:10.1002/hbm.22515

    PubMed  Google Scholar 

  152. McMillan CT, Brun C, Siddiqui S, Churgin M, Libon D, Yushkevich P, Zhang H, Boller A, Gee J, Grossman M (2012) White matter imaging contributes to the multimodal diagnosis of frontotemporal lobar degeneration. Neurology 78:1761–1768. doi:10.1212/WNL.0b013e31825830bd

    PubMed Central  CAS  PubMed  Google Scholar 

  153. McMillan CT, Toledo JB, Avants BB, Cook PA, Wood EM, Suh E, Irwin DJ, Powers J, Olm C, Elman L et al (2014) Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiol Aging 35:1473–1482. doi:10.1016/j.neurobiolaging.2013.11.029

    PubMed Central  CAS  PubMed  Google Scholar 

  154. Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH (2014) Asymmetry and heterogeneity of Alzheimer’s and frontotemporal pathology in primary progressive aphasia. Brain 137:1176–1192. doi:10.1093/brain/awu024

    PubMed  Google Scholar 

  155. Meyer H, Bug M, Bremer S (2012) Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol 14:117–123. doi:10.1038/ncb2407

    CAS  PubMed  Google Scholar 

  156. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67:953–966. doi:10.1016/j.neuron.2010.08.044

    PubMed Central  CAS  PubMed  Google Scholar 

  157. Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J et al (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345:1192–1194. doi:10.1126/science.1256800

    CAS  PubMed  Google Scholar 

  158. Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, Isaacs AM (2013) C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol 126:845–857. doi:10.1007/s00401-013-1200-z

    PubMed Central  CAS  PubMed  Google Scholar 

  159. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11. doi:10.1007/s00401-011-0910-3

    PubMed Central  CAS  PubMed  Google Scholar 

  160. Montpetit V, Clapin DF, Guberman A (1985) Substructure of 20 nm filaments of progressive supranuclear palsy. Acta Neuropathol 68:311–318

    CAS  PubMed  Google Scholar 

  161. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C et al (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339:1335–1338. doi:10.1126/science.1232927

    CAS  PubMed  Google Scholar 

  162. Morris HR, Baker M, Yasojima K, Houlden H, Khan MN, Wood NW et al (2002) Analysis of tau haplotypes in Pick’s disease. Neurology 59:443–445

    CAS  PubMed  Google Scholar 

  163. Mukherjee O, Pastor P, Cairns NJ, Chakraverty S, Kauwe JS, Shears S, Behrens MI, Budde J, Hinrichs AL, Norton J et al (2006) HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol 60:314–322. doi:10.1002/ana.20963

    PubMed Central  CAS  PubMed  Google Scholar 

  164. Munoz-Garcia D, Ludwin SK (1984) Classic and generalized variants of Pick’s disease: a clinicopathological, ultrastructural, and immunocytochemical comparative study. Ann Neurol 16:467–480. doi:10.1002/ana.410160408

    CAS  PubMed  Google Scholar 

  165. Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, Kuroda S, Mackenzie IR (2009) FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118:617–627. doi:10.1007/s00401-009-0598-9

    CAS  PubMed  Google Scholar 

  166. Murray R, Neumann M, Forman MS, Farmer J, Massimo L, Rice A, Miller BL, Johnson JK, Clark CM, Hurtig HI et al (2007) Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 68:1274–1283. doi:10.1212/01.wnl.0000259519.78480.c3

    CAS  PubMed  Google Scholar 

  167. Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114:221–229. doi:10.1007/s00401-007-0261-2

    CAS  PubMed  Google Scholar 

  168. Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, Thomason PC, Neltner JH, Smith CD, Santacruz KS et al (2011) Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 134:1506–1518. doi:10.1093/brain/awr053

    PubMed Central  PubMed  Google Scholar 

  169. Neumann M (2013) Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences. Revue Neurol 169:793–798. doi:10.1016/j.neurol.2013.07.019

    CAS  Google Scholar 

  170. Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, Roeber S, Kretzschmar HA, Munoz DG, Kusaka H et al (2011) FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134:2595–2609. doi:10.1093/brain/awr201

    PubMed Central  PubMed  Google Scholar 

  171. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS, Troost D, Kretzschmar HA, Trojanowski JQ et al (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117:137–149. doi:10.1007/s00401-008-0477-9

    PubMed Central  CAS  PubMed  Google Scholar 

  172. Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:605–616. doi:10.1007/s00401-009-0581-5

    PubMed Central  CAS  PubMed  Google Scholar 

  173. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133. doi:10.1126/science.1134108

    CAS  PubMed  Google Scholar 

  174. Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T, Yoshida M, Murayama S, Mann DM, Akiyama H et al (2013) Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep 4:124–134. doi:10.1016/j.celrep.2013.06.007

    CAS  PubMed  Google Scholar 

  175. Onyike CU, Diehl-Schmid J (2013) The epidemiology of frontotemporal dementia. Int Rev Psychiatry 25:130–137. doi:10.3109/09540261.2013.776523

    PubMed Central  PubMed  Google Scholar 

  176. Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69:3584–3596

    PubMed Central  CAS  PubMed  Google Scholar 

  177. Proudfoot M, Gutowski NJ, Edbauer D, Hilton DA, Stephens M, Rankin J, Mackenzie IR (2014) Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathol 127:451–458. doi:10.1007/s00401-014-1245-7

    CAS  PubMed  Google Scholar 

  178. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, O’Neil JP, Lal RA, Dronkers NF, Miller BL et al (2008) Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 64:388–401. doi:10.1002/ana.21451

    PubMed Central  PubMed  Google Scholar 

  179. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477. doi:10.1093/brain/awr179

    PubMed Central  PubMed  Google Scholar 

  180. Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002) The prevalence of frontotemporal dementia. Neurology 58:1615–1621

    CAS  PubMed  Google Scholar 

  181. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268. doi:10.1016/j.neuron.2011.09.010

    PubMed Central  CAS  PubMed  Google Scholar 

  182. Robinson JL, Geser F, Stieber A, Umoh M, Kwong LK, Van Deerlin VM, Lee VM, Trojanowski JQ (2013) TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol 125:121–131. doi:10.1007/s00401-012-1055-8

    PubMed Central  CAS  PubMed  Google Scholar 

  183. Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E et al (2011) Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 134:2565–2581. doi:10.1093/brain/awr198

    PubMed Central  PubMed  Google Scholar 

  184. Rollinson S, Mead S, Snowden J, Richardson A, Rohrer J, Halliwell N, Usher S, Neary D, Mann D, Hardy J et al (2011) Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. Neurobiol Aging 32(758):e751–e757. doi:10.1016/j.neurobiolaging.2010.12.005

    Google Scholar 

  185. Rosso SM, Landweer EJ, Houterman M, Donker Kaat L, van Duijn CM, van Swieten JC (2003) Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case-control study. J Neurol Neurosurg Psychiatry 74:1574–1576

    PubMed Central  CAS  PubMed  Google Scholar 

  186. Russ J, Liu EY, Wu K, Neal D, Suh E, Irwin DJ, McMillan CT, Harms MB, Cairns NJ, Wood EMet al (2014) Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol. doi:10.1007/s00401-014-1365-0

  187. Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, Yamanouchi H, Murayama S (2004) Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 63:911–918

    PubMed  Google Scholar 

  188. Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, Bruce J, Grossman M, Trojanowski JQ, Lee VM (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 169:1343–1352. doi:10.2353/ajpath.2006.060438

    PubMed Central  CAS  PubMed  Google Scholar 

  189. Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF (2012) The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol 124:693–704. doi:10.1007/s00401-012-1017-1

    PubMed Central  CAS  PubMed  Google Scholar 

  190. Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL et al (2014) Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 75:116–126. doi:10.1002/ana.24052

    PubMed Central  CAS  PubMed  Google Scholar 

  191. Sha SJ, Takada LT, Rankin KP, Yokoyama JS, Rutherford NJ, Fong JC, Khan B, Karydas A, Baker MC, DeJesus-Hernandez M et al (2012) Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology 79:1002–1011. doi:10.1212/WNL.0b013e318268452e

    PubMed Central  PubMed  Google Scholar 

  192. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65:403–413. doi:10.1002/ana.21610

    PubMed Central  CAS  PubMed  Google Scholar 

  193. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA et al (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121:597–609. doi:10.1007/s00401-011-0808-0

    PubMed Central  CAS  PubMed  Google Scholar 

  194. Simon-Sanchez J, Dopper EG, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, de Graaf JR, de Koning I, van Schoor NM, Deeg DJ et al (2012) The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain 135:723–735. doi:10.1093/brain/awr353

    PubMed  Google Scholar 

  195. Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, Kilander L, Religa D, Wimo A, Winblad B et al (2014) CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83:1945–1953. doi:10.1212/WNL.0000000000001015

    PubMed  Google Scholar 

  196. Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, Peeters K, Mattheijssens M, Cruts M, Vandenberghe R et al (2009) Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol 65:603–609. doi:10.1002/ana.21621

    CAS  PubMed  Google Scholar 

  197. Snowden J, Neary D, Mann D (2007) Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 114:31–38. doi:10.1007/s00401-007-0236-3

    PubMed  Google Scholar 

  198. Snowden JS, Hu Q, Rollinson S, Halliwell N, Robinson A, Davidson YS, Momeni P, Baborie A, Griffiths TD, Jaros E et al (2011) The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol 122:99–110. doi:10.1007/s00401-011-0816-0

    CAS  PubMed  Google Scholar 

  199. Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AM, Jones M, Gerhard A, Davidson YS, Robinson A et al (2012) Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135:693–708. doi:10.1093/brain/awr355

    PubMed Central  PubMed  Google Scholar 

  200. Steinacker P, Hendrich C, Sperfeld AD, Jesse S, von Arnim CA, Lehnert S, Pabst A, Uttner I, Tumani H, Lee VM et al (2008) TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 65:1481–1487. doi:10.1001/archneur.65.11.1481

    PubMed Central  PubMed  Google Scholar 

  201. Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, Murphy J, Shoesmith C, Rosenfeld J, Leigh PN et al (2009) Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10:131–146

    PubMed  Google Scholar 

  202. Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P et al (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83:1043–1050. doi:10.1016/j.neuron.2014.07.041

    CAS  PubMed  Google Scholar 

  203. Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, Lee VM, Shaw LM, Trojanowski JQ (2012) CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 124:23–35. doi:10.1007/s00401-012-0983-7

    PubMed Central  CAS  PubMed  Google Scholar 

  204. Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, Seelaar H, Van Swieten JC, Brown JM, Johannsen P et al (2010) FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 120:33–41. doi:10.1007/s00401-010-0698-6

    PubMed Central  PubMed  Google Scholar 

  205. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67:555–564. doi:10.1097/NEN.0b013e31817713b5

    PubMed Central  CAS  PubMed  Google Scholar 

  206. van Blitterswijk M, Mullen B, Wojtas A, Heckman MG, Diehl NN, Baker MC, DeJesus-Hernandez M, Brown PH, Murray ME, Hsiung GY et al (2014) Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol Neurodegener 9:38. doi:10.1186/1750-1326-9-38

    PubMed Central  PubMed  Google Scholar 

  207. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M et al (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 7:409–416. doi:10.1016/S1474-4422(08)70071-1

    PubMed Central  PubMed  Google Scholar 

  208. Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M et al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42:234–239. doi:10.1038/ng.536

    PubMed Central  PubMed  Google Scholar 

  209. van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S, Vandenberghe R, Santens P, Van den Broeck M, Joris G, Brys J et al (2011) TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134:808–815. doi:10.1093/brain/awr007

    PubMed Central  PubMed  Google Scholar 

  210. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P et al (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208–1211. doi:10.1126/science.1165942

    CAS  PubMed  Google Scholar 

  211. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C et al (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimer’s Dement J Alzheimer’s Assoc 8:65–73. doi:10.1016/j.jalz.2011.07.004

    CAS  Google Scholar 

  212. Villela D, Kimura L, Schlesinger D, Goncalves A, Pearson PL, Suemoto CK, Pasqualucci C, Krepischi AC, Grinberg LT, Rosenberg C (2013) Germline DNA copy number variation in individuals with Argyrophilic grain disease reveals CTNS as a plausible candidate gene. Genet Mol Biol 36:498–501. doi:10.1590/S1415-47572013000400006

    PubMed Central  CAS  PubMed  Google Scholar 

  213. Wakabayashi K, Oyanagi K, Makifuchi T, Ikuta F, Homma A, Homma Y, Horikawa Y, Tokiguchi S (1994) Corticobasal degeneration: etiopathological significance of the cytoskeletal alterations. Acta Neuropathol 87:545–553

    CAS  PubMed  Google Scholar 

  214. Watts GD, Thomasova D, Ramdeen SK, Fulchiero EC, Mehta SG, Drachman DA, Weihl CC, Jamrozik Z, Kwiecinski H, Kaminska A et al (2007) Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 72:420–426. doi:10.1111/j.1399-0004.2007.00887.x

    CAS  PubMed  Google Scholar 

  215. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36:377–381. doi:10.1038/ng1332

    CAS  PubMed  Google Scholar 

  216. Whitwell JL, Josephs KA (2011) Neuroimaging in frontotemporal lobar degeneration—predicting molecular pathology. Nat Rev Neurol 8:131–142. doi:10.1038/nrneurol.2012.7

    Google Scholar 

  217. Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, Bennett DA, Schneider JA (2013) TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 70:1418–1424. doi:10.1001/jamaneurol.2013.3961

    PubMed  Google Scholar 

  218. Wood EM, Falcone D, Suh E, Irwin DJ, Chen-Plotkin AS, Lee EB, Xie SX, Van Deerlin VM, Grossman M (2013) Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. doi:10.1001/jamaneurol.2013.3956

  219. Yoshiyama Y, Lee VM, Trojanowski JQ (2013) Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 84:784–795. doi:10.1136/jnnp-2012-303144

    PubMed Central  PubMed  Google Scholar 

  220. Zhang YJ, Jansen-West K, Xu YF, Gendron TF, Bieniek KF, Lin WL, Sasaguri H, Caulfield T, Hubbard J, Daughrity L et al (2014) Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol 128:505–524. doi:10.1007/s00401-014-1336-5

    PubMed Central  CAS  PubMed  Google Scholar 

  221. Zhukareva V, Joyce S, Schuck T, Van Deerlin V, Hurtig H, Albin R, Gilman S, Chin S, Miller B, Trojanowski JQ et al (2006) Unexpected abundance of pathological tau in progressive supranuclear palsy white matter. Ann Neurol 60:335–345. doi:10.1002/ana.20916

    CAS  PubMed  Google Scholar 

  222. Zhukareva V, Mann D, Pickering-Brown S, Uryu K, Shuck T, Shah K, Grossman M, Miller BL, Hulette CM, Feinstein SC et al (2002) Sporadic Pick’s disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol 51:730–739. doi:10.1002/ana.10222

    PubMed  Google Scholar 

  223. Zhukareva V, Shah K, Uryu K, Braak H, Del Tredici K, Sundarraj S, Clark C, Trojanowski JQ, Lee VM (2002) Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer’s disease, and Pick’s disease: a comparative study. Am J Pathol 161:1135–1141

    PubMed Central  CAS  PubMed  Google Scholar 

  224. Zhukareva V, Trojanowski JQ, Lee VM (2004) Assessment of pathological tau proteins in frontotemporal dementias: qualitative and quantitative approaches. Am J Geriatr Psychiatry 12:136–145

    PubMed  Google Scholar 

Download references

Acknowledgments

Support for this work was provided by grants from the National Institute on Aging of the National Institutes of Health (PO1-AG03991 and P50-AG05681) and from the Alzheimer’s Drug Discovery Foundation to NJC and P30-AG10124 (JQT and VMV), PO1-AG17586 (JQT, VMV, and VM-YL), PO1-AG032953 (JQT, VMV, and VM-YL) and NS088341 (DJI). We would also like to thank the members of the Knight Alzheimer’s Disease Research Center, Washington University, St. Louis, MO, and the Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA, who contributed to the work, and the many patients studied and their families, for making the research reviewed here possible.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Institute on Ageing, University of Pennsylvania School of Medicine, HUP Maloney 3rd Floor, 36th and Spruce Streets, Philadelphia, PA, 19104-4283, USA

    David J. Irwin, Vivianna M. Van Deerlin, Virginia M.-Y. Lee & John Q. Trojanowski

  2. Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, 19104, USA

    David J. Irwin, Murray Grossman & Corey T. McMillan

  3. Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Edward B. Lee

  4. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 63110, USA

    Nigel J. Cairns

Authors
  1. David J. Irwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nigel J. Cairns
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Murray Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Corey T. McMillan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edward B. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vivianna M. Van Deerlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Virginia M.-Y. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John Q. Trojanowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Q. Trojanowski.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Irwin, D.J., Cairns, N.J., Grossman, M. et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol 129, 469–491 (2015). https://doi.org/10.1007/s00401-014-1380-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-014-1380-1

Keywords

Search

Navigation